Clinical Effect of Penbutolol(Betapressin(R))on Hypertensive Patients.
10.4070/kcj.1989.19.2.333
- Author:
Jong Chun PARK
;
Gwang Chae GILL
;
Chan Hyung PARK
;
Soon Chul SHIN
;
Seung Jin YANG
;
Myung Ho JEONG
;
Jeong Gwan CHO
;
Jung Chaee KANG
- Publication Type:Original Article
- Keywords:
Hypertension;
Penbutolol
- MeSH:
Blood Pressure;
Dizziness;
Drug Therapy;
Electrocardiography;
Exanthema;
Female;
Heart Rate;
Humans;
Hypertension;
Joints;
Korea;
Male;
Penbutolol;
Pheniramine;
Quality of Life;
Sex Distribution
- From:Korean Circulation Journal
1989;19(2):333-342
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The only clinically avilable levo-isomer type of beta-recepter blocker is penbutolol sulfate, and it is already accepted as one of beta-receptor blockers for initial antihypertensive drug therapy according to the report of 1988 Joint National Committee on Detection, Evaluation, and Tratment of High Blood Pressure. To evaluate the antihypertensive efficacy, effect on the quqlity of life, and side effects of penbutolol recently introduced into Korea, penbutolol was administered to 29 essential hypertensive(mild 9, moderate10, and severe 10) patients for 12 weeks or longer. The result of the clinical analysis are as follows; 1) The mean age was 50.0+/-10.9(M+/-SD), and the sex distribution between male and female was16:13. 2) The blood pressure lowering effects of penbutolol as a monotherapy were marked in 16, moderate in 6, and insignificant in 2 cases. The systolic blood pressure was significantly decreased from 179.1+/-20.2 to 135.4+/-16.5mmHg(P<0.005), and the diastolic blood pressure from 112.6+/-13.5 to 84.0+/-11.9mmHg(P<0.005)after 12 weeks' penbutolol therapy. 3) The heart rate was significantly decreased from70.3+/-13.3 to 65.5+/-9.1 per minute(P<0.05). 4) The quality of life was improved markely in 5(17.2%) and slightly in 8 cases(29.6%). 5) There were no significant laboratory changes after 12 weeks' penbutolol therapy. 6) Two out of three cases with non-specific ST segment and T wave changes in EKG and two out of 9 cases with EKG were normalized, 2 cases of LAH with strain were improved. 7) The side effects of penbutolol were dizziness in 4, sexual dysfunction in 2, and skin rash in 1 case. 8) Final multifarious assessment of penbutolol therapy showed that it was very useful in 11(37.9%), useful in 4(13.8%) and slightly useful in 7 cases(24.1%). These reult suggest that penbutolol is a first-line antihypertensive agent with an effective antihypertensive action, improving quality of life, with no significant laboratory changes and few side effects.
